Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab +- bevacizumab + carboplatin-paclitaxel in metastatic NSCLC
Atezolizumab;Bevacizumab;Carboplatin;Paclitaxel
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab +- bevacizumab + carboplatin-paclitaxel in metastatic NSCLC ### Output: Atezolizumab;Bevacizumab;Carboplatin;Paclitaxel